Chromocell Therapeutics Corporation (CHRO) - Total Liabilities
Based on the latest financial reports, Chromocell Therapeutics Corporation (CHRO) has total liabilities worth $7.32 Million USD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore CHRO year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Chromocell Therapeutics Corporation - Total Liabilities Trend (2020–2024)
This chart illustrates how Chromocell Therapeutics Corporation's total liabilities have evolved over time, based on quarterly financial data.
Chromocell Therapeutics Corporation Competitors by Total Liabilities
The table below lists competitors of Chromocell Therapeutics Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tay Ninh Cable Car Tour Co.
VN:TCT
|
Vietnam | ₫11.56 Billion |
|
Kore Mining Ltd
V:KORE
|
Canada | CA$3.25 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥216.30 Million |
|
Aqua Metals Inc
NASDAQ:AQMS
|
USA | $3.99 Million |
|
Raytech Holding Limited Ordinary Shares
NASDAQ:RAY
|
USA | $28.77 Million |
|
Kumpulan Jetson Bhd
KLSE:9083
|
Malaysia | RM98.64 Million |
|
Chuan Huat Resources Bhd
KLSE:7016
|
Malaysia | RM319.65 Million |
|
Auga Group AB
STU:W9Z
|
Germany | €172.99 Million |
Liability Composition Analysis (2020–2024)
This chart breaks down Chromocell Therapeutics Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see CHRO market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.11 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 8.89 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Chromocell Therapeutics Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Chromocell Therapeutics Corporation (2020–2024)
The table below shows the annual total liabilities of Chromocell Therapeutics Corporation from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $4.08 Million | -37.57% |
| 2023-12-31 | $6.54 Million | 0.00% |
| 2023-09-30 | $6.54 Million | +73.89% |
| 2022-12-31 | $3.76 Million | 0.00% |
| 2022-09-30 | $3.76 Million | +2.21% |
| 2021-12-31 | $3.68 Million | 0.00% |
| 2021-09-30 | $3.68 Million | +0.83% |
| 2020-12-31 | $3.65 Million | 0.00% |
| 2020-09-30 | $3.65 Million | -- |
About Chromocell Therapeutics Corporation
Channel Therapeutics Corporation, a clinical-stage biotech company, develops and commercializes new therapeutics to alleviate pain. It targets sodium ion-channel NaV1.7; and develops NaV blockers that target the body's peripheral nervous system. The company's lead compound is CC8464, which has completed Phase 1 clinical trials for the treatment of moderate-to-severe pain in erythromelalgia and id… Read more